Description
Tirzepatide 60 mg — Dual GIP/GLP-1 Receptor Agonist for Metabolic Research
Tirzepatide is a synthetic dual receptor agonist designed to activate
both the GIP (glucose-dependent insulinotropic polypeptide) receptor and the
GLP-1 (glucagon-like peptide-1) receptor. In preclinical and clinical research,
it has been investigated for its effects on glycemic control, body weight, and
cardiometabolic risk factors in obesity and type 2 diabetes models.
What It Is
- Class: Dual GIP/GLP-1 receptor agonist (incretin mimetic)
- Concept: Combines signaling from both incretin pathways to enhance
glucose-dependent insulin secretion and modulate appetite, weight, and metabolic markers. - Format: Research-grade synthetic peptide supplied as a lyophilized powder.
Proposed Mechanisms (Preclinical)
Incretin & Islet Biology
- GIP receptor activation: Studied for potentiation of
glucose-dependent insulin secretion and effects on ?-cell function
in metabolic models. - GLP-1 receptor activation: Investigated for improvements in
insulin secretion, reduced inappropriate glucagon release, and slowed gastric emptying. - Dual agonism is explored for synergistic effects vs. single-receptor
incretin agonists.
Body Weight & Metabolic Effects
- Acts on central pathways involved in appetite and satiety, with
associated reductions in caloric intake in research settings. - Evaluated for changes in body weight, fat mass, and waist circumference
in obesity-related models. - Ongoing interest in effects on lipids, liver fat, inflammatory markers,
and overall cardiometabolic risk.
Selected Research Highlights
- Type 2 Diabetes: Dual GIP/GLP-1 agonism has been studied for robust
reductions in HbA1c, fasting glucose, and post-prandial glycemic excursions compared with
certain established comparators. - Obesity & Weight Management: Research reports substantial
weight loss and favorable changes in body composition under tirzepatide
exposure in obesity cohorts. - Liver & NAFLD/NASH: Experimental and clinical work has evaluated
liver fat content, transaminases, and nonalcoholic fatty-liver disease markers. - Cardiometabolic Parameters: Studies have examined effects on blood
pressure, lipids, and other cardiovascular risk factors in high-risk populations.
Chemical & Handling Information
- Type: Synthetic dual incretin receptor agonist
- Targets: GIP receptor and GLP-1 receptor
- Appearance: White to off-white lyophilized powder
Specifications
- Peptide: Tirzepatide
- Amount: 60 mg per vial
- Form: Lyophilized powder
- Purity: ?99% (HPLC); COA per lot available
- Packaging: Sealed vials suitable for standard laboratory handling
Storage & Stability
- Store lyophilized vials in a cool, dry place, protected from light.
- Refrigeration or freezing of the lyophilized peptide is recommended for extended stability,
according to laboratory SOPs. - After reconstitution, store at 2–8 °C for short-term use.
- For long-term storage, aliquot and freeze at ?20 °C or below; avoid repeated freeze–thaw cycles.
Reviews
There are no reviews yet.